Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 12/20 | 0.53 |
| ▸ | LMNA | P02545 | 7/20 | 0.53 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.53 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 9/20 | 0.50 |
| ▸ | HPGD | P15428 | 6/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.50 |
| ▸ | TLR9 | Q9NR96 | 2/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 1/20 | 0.50 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.50 |
| ▸ | RAB9A | P51151 | 1/20 | 0.50 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3775139 | 0.90 | ALDH1A1 (0.50) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL11785719 | 0.89 | PLA2G4B (0.53) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL531660 | 0.88 | ALDH1A1 (0.54) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10928328 | 0.85 | ALDH1A1 (0.47) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL10928329 | 0.85 | ALDH1A1 (0.47) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL662081 | 0.85 | ALDH1A1 (0.57) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL182652 | 0.84 | MAPT (0.52) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL27606455 | 0.84 | ALDH1A1 (0.53) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL2555859 | 0.84 | MEN1 (0.61) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 | |
| SCHEMBL6960 | 0.83 | ALDH1A1 (0.56) | ALDH1A1LMNACYP1A2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11603349-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD (AU) | 2023-03-14 | — | — | US | disclosed |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD (AU) | 2021-08-12 | — | — | US | disclosed |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD (AU) | 2021-08-12 | — | — | US | disclosed |
| US-11014873-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD. (AU) | 2021-05-25 | — | — | US | disclosed |
| US-11014873-B2 | Anti-fibrotic compounds | CERTA THERAPEUTICS PTY LTD. (AU) | 2021-05-25 | — | — | US | disclosed |
| EP-2906216-B1 | INHIBITORS OF DNA GYRASE FOR THE TREATMENT OF BACTERIAL INFECTIONS | KUMAR AJAY (GB) | 2020-06-24 | — | — | EP | disclosed |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-02-20 | — | — | US | disclosed |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | SHIRE HUMAN GENETIC THERAPIES, INC. | 2020-02-20 | — | — | US | disclosed |
| WO-2018144620-A9 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD. (AU) | 2019-01-24 | — | — | WO | disclosed |
| WO-2018144620-A9 | ANTI-FIBROTIC COMPOUNDS | CERTA THERAPEUTICS PTY LTD. (AU) | 2019-01-24 | — | — | WO | disclosed |
| US-7141564-B2 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2006-11-28 | — | — | US | disclosed |
| EP-1569653-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | Warner-Lambert Company LLC (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20040171620-A1 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-09-02 | — | — | US | disclosed |
| US-20040138219-A1 | Quinolines and nitrogenated derivative therof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-07-15 | — | — | US | disclosed |
| WO-2004052373-A1 | BENZOXAZIN-3-ONES AND DERIVATIVES THEREOF AS INHIBITORS OF PI3K | WARNER-LAMBERT COMPANY LLC (US) | 2004-06-24 | — | — | WO | disclosed |
| US-20040121996-A1 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | BARVIAN NICOLE (US) | 2004-06-24 | — | — | US | disclosed |
| EP-1399443-A1 | NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM PLC (GB) | 2004-03-24 | — | — | EP | disclosed |
| EP-1359908-A1 | QUINOLINES AND NITROGENATED DERIVATIVES THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM PLC (GB) | 2003-11-12 | — | — | EP | disclosed |
| WO-2003087098-A1 | NITROGEN-CONTAINING BICYCLIC HETEROCYCLES FOR USE AS ANTIBACTERIALS | SMITHKLINE BEECHAM P.L.C. (GB) | 2003-10-23 | — | — | WO | disclosed |
| WO-2002056882-A1 | QUINOLINES AND NITROGENATED DERIVAIVE THEREOF SUBSTITUTED IN 4-POSITION BY A PIPERIDINE-CONTAINING MOIETY AND THEIR USE AS ANTIBACTERIAL AGENTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2002-07-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040171620-A1 | Nitrogen-containing bicyclic heterocycles for use as antibacterials | NRDC, NUCB2, NDC1 | ALDH1A1 3787/4885LMNA 2737/4885CYP1A2 1387/4885 |
| US-20040121996-A1 | Benzoxazin-3-ones and derivatives thereof as therapeutic agents | XDH, HAX1, CYP4X1 | ALDH1A1 782/4885LMNA 695/4885CYP1A2 269/4885 |
| US-11603349-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, TGFB2 | ALDH1A1 1274/4885LMNA 580/4885CYP1A2 4019/4885 |
| US-20210246100-A1 | ANTI-FIBROTIC COMPOUNDS | TGFB1, SMAD3, TGFB2 | ALDH1A1 1274/4885LMNA 580/4885CYP1A2 4019/4885 |
| US-11014873-B2 | Anti-fibrotic compounds | TGFB1, SMAD3, SMAD2 | ALDH1A1 1184/4885LMNA 654/4885CYP1A2 4174/4885 |
| US-20200055814-A1 | ANTI-FIBROTIC COMPOUNDS | TGFB1, SMAD3, SMAD2 | ALDH1A1 1967/4885LMNA 652/4885CYP1A2 4445/4885 |
| US-20040138219-A1 | Quinolines and nitrogenated derivative therof substituted in 4-position by a piperidine-containing moiety and their use as antibacterial agents | NCF1, TEAD1, TYMS | ALDH1A1 1742/4885LMNA 2504/4885CYP1A2 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.